TLL-018,Tofacitinib
pfizer,highlightll pharmaceutical
['tofacitinib', ' hs ', 'tofa', 'rheumatoid,arthritis']
#eular2023 #lb0001 data from phase 2 rct in china showed novel therapy, tll-018, dual jak1/tyk2-i showed superior response to tofacitinib. safety profile were similar. interesting to see data in phase 3. may be an option for difficult to treat rheumatoid arthritis 
Rheumatologist. Interested in B-cells, Lupus, Sjogren, Pre-Connective Tissue Disease, Tennis, Running & Travelling 🌏